Jesse H. Wright, MD, PhD reflects on his groundbreaking contributions to cognitive behavior therapy and the evolution of psychiatric education over 5 decades.

Mental health professionals face disaster fatigue amid ongoing crises, struggling with emotional exhaustion and compassion fatigue while seeking effective solutions.

Panelists discuss the importance of setting realistic expectations when initiating pitolisant for narcolepsy, emphasizing consistent daily use, gradual titration, and patient-centered measures of success, while accounting for external stressors, lifestyle factors, and the need for occupational accommodations to support long-term functional outcomes.

Panelists discuss how behavioral strategies—including structured sleep routines, scheduled naps, dietary adjustments, light therapy, and cognitive behavioral support—are essential components of comprehensive narcolepsy management, reinforcing that individualized, nonpharmacologic interventions can significantly improve daily function and long-term outcomes.

Clinicians explore the potential of xenomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Dr. Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.

Innovative approaches enhance understanding of tardive dyskinesia's impact on patients' lives, shifting focus from detection to functional well-being.

Clinician discusses the importance of maximizing medication doses and trial periods for effectively managing tardive dyskinesia at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Yvette Elpidio, PMHNP-BC, shares insights on NMDA agonists at the Southern California Psychiatry conference.

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.

"Fifteen seconds, thirty, a minute of silence, sweat weeps from the intern’s forehead..."

The new movie "Superman: Legacy" addresses modern social challenges and potential mental health themes.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

Fava beans emerge as a powerful natural source of L-DOPA, offering potential benefits for mood disorders and Parkinson's disease and holding enriching culinary traditions.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

The psychological impact of national tragedies: it's time to recognize the importance of mourning and finding meaning in collective grief.